Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Common Equity: 2010-2024

Historic Common Equity for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to $23.5 million.

  • Sunshine Biopharma's Common Equity fell 3.35% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 3.35%. This contributed to the annual value of $23.5 million for FY2024, which is 10.81% up from last year.
  • As of FY2024, Sunshine Biopharma's Common Equity stood at $23.5 million, which was up 10.81% from $21.2 million recorded in FY2023.
  • Over the past 5 years, Sunshine Biopharma's Common Equity peaked at $23.5 million during FY2024, and registered a low of -$954,837 during FY2020.
  • For the 3-year period, Sunshine Biopharma's Common Equity averaged around $22.1 million, with its median value being $21.6 million (2022).
  • Its Common Equity has fluctuated over the past 5 years, first fell by 29.84% in 2020, then soared by 10,117.97% in 2022.
  • Over the past 5 years, Sunshine Biopharma's Common Equity (Yearly) stood at -$954,837 in 2020, then spiked by 122.17% to $211,662 in 2021, then surged by 10,117.97% to $21.6 million in 2022, then dropped by 1.94% to $21.2 million in 2023, then increased by 10.81% to $23.5 million in 2024.